receptor targets comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-11-18. Where a claim depends on a specific study, the study is described rather than over-claimed.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
开发进程从早期单次和多次给药研究推进至大规模后期试验。公开报告显示，参与者在体重和相关代谢指标上出现变化，但完整数据需经同行评审并接受独立复核。试验设计通常包括随机、双盲和对照设置，以区分药物效应与行为干预。监管提交和标签范围尚未确定；长期维持效果与心血管结局仍是开放问题。
与仅靶向单一受体的同类药物相比，瑞他鲁肽增加胰高血糖素受体成分，理论上可提高能量消耗并改变脂肪分布。临床中观察到的体重变化是否主要来自该额外机制，目前尚无定论。胃肠道反应是该类药物常见不良事件，试验中通过剂量递增和监测进行管理。停药后体重反弹、个体差异和长期耐受性仍需更多数据。
瑞他鲁肽是一种在研合成肽，同时作用于胰高血糖素样肽-1、葡萄糖依赖性促胰岛素多肽和胰高血糖素受体。该分子属于多受体激动剂类别，尚未获得任何监管机构的上市批准。当前临床开发主要针对肥胖和2型糖尿病，研究代号为LY3437943。已确立的信息包括受体靶点和部分中期试验结果；最终疗效、长期安全性和适用人群仍属开放问题。
| Property | Value | Notes |
|---|---|---|
| Receptor targets | GIP, GLP-1, glucagon | One molecule activates all three pathways |
| Research identifier | LY3437943 | Code used in published trial reports |
| Development stage | Phase 3, reported as ongoing | Not approved by any regulatory agency |
| Route studied | Subcutaneous | Administration form used in clinical trials |
| Studied populations | Adults with obesity or type 2 diabetes | Enrollment criteria vary between trials |
Published information places retatrutide in clinical development rather than on the market as an approved therapy. Early-stage and mid-stage trials have examined tolerability and changes in body weight, and larger studies continue to report results over time. Open questions include the durability of effects after treatment stops, the composition of weight lost, and cardiovascular outcomes over long periods. Statements about definitive benefit should therefore be treated as provisional. Regulatory status varies by jurisdiction and changes as applications are reviewed.
Retatrutide is an investigational synthetic peptide designed to activate three distinct receptor systems within a single molecule. Its pharmacological profile combines activity at the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor. This arrangement places it within a broader class of agents often described as multi-agonists, which contrast with compounds that engage one or two targets. Research interest centers on whether simultaneous signaling produces effects that single-receptor agonists cannot achieve alone. A single molecular entity also simplifies manufacturing and delivery logistics compared with combining separate agents.
Mechanistic proposals link each receptor to a different physiological role. Activation of the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors is associated with reduced appetite, slower gastric emptying, and glucose-dependent insulin release. Glucagon receptor signaling, by contrast, is associated with increased energy expenditure and altered lipid handling, though it can also raise blood glucose. The design intent is to balance these contributions so that weight reduction is enhanced without unacceptable glycemic trade-offs. How well that balance holds across individuals is not fully resolved.
Each receptor contributes a different physiological effect. Activation of the GLP-1 receptor slows gastric emptying and reduces appetite signaling in the brain. GIP receptor activity influences insulin secretion and lipid handling, while glucagon receptor stimulation raises energy use and fat oxidation. Combining these pathways is intended to produce weight loss beyond what single- or dual-receptor agonists achieve. Researchers attribute the observed potency to simultaneous engagement of all three targets, though the exact contribution of each receptor to overall effect remains under investigation.
Clinical development has advanced through phase 2 trials in adults with obesity and type 2 diabetes. Reported phase 2 results described substantial average weight reduction over roughly forty-eight weeks of weekly dosing. A phase 3 program is ongoing to confirm efficacy and assess long-term safety. Because the compound has not received regulatory approval, it is not available as a prescription product. Public discussion of retatrutide often conflates trial findings with marketed status, an important distinction when interpreting coverage of the topic.
== C == C terminus - Can f 1 - cancer - candidate gene - Canonical sequence - cap - cap site - carbon-monoxide dehydrogenase (cytochrome b-561) - carboxyl terminus - carcinoma - carnitine dehydratase - carrier - carveol dehydrogenase - Catalog of MCA Control Patterns - CAT assay - CAT RNA-binding domain - catalase-related immune-responsive domain - CCAAT box - Cd2+-exporting ATPase - cDNA - cDNA clone - cDNA library - CDP-acylglycerol O-arachidonoyltransferase - cell - centimorgan - centromere - chain terminator - channel-conductance-controlling ATPase - chaperone protein - chlordecone reductase - chloroplast protein-transporting ATPase - cholestanetriol 26-monooxygenase - cholesterol 7alpha-monooxygenase - chromosome - chromosomal translocation - chromosome walking - CIROP gene - CIS - cistron - clone (genetics) - clone (noun) - clone (verb) - cloning - CmERG1 - coding sequence - coding strand - codon - codon usage bias - competent - complementary - conformational epitope - congenital - consensus sequence - conservative substitution - conserved - contig - coproporphyrinogen dehydrogenase - cortisone alpha-reductase - cosmid - costunolide synthase - CpG - craniosynostosis - crp domain - Cu2+-exporting ATPase - cyclodeaminase domain - cyclohexanol dehydrogenase - cyclopeptine synthase - cystic fibrosis - cytogenetic map - cytosine -
While the character is usually physically invincible, he demonstrates emotional and psychological vulnerability, exemplifying values and aspirations of resilience for his audience. Flores notes that Wolverine's fanbase consists primarily of men and the character generally exemplifies a masculine perspective on recovery from trauma; despite this, she found him therapeutic in her own recovery from rape. Nnedi Okorafor, a Nigerian American science-fiction author, stated that Wolverine was a therapeutic role model for her during her experience of paralysis following surgical treatment of scoliosis. J. Andrew Deman praises "The Wounded Wolf" story illustrated by Windsor-Smith that appeared in Uncanny X-Men, comparing it to the Iliad. Comic book critics have particularly commended Windsor-Smith's Weapon X story, which describes Wolverine's mistreatment at the hands of the Weapon X program and his experience of trauma. Hagai Palevsky describes it as "quite possibly the best comic Marvel ever published." Rolling Stone journalist Sean T. Collins calls it "Arguably the most important and the most visually impressive Wolverine storyline of all time." In contrast, Paul Young criticizes the trends of the mid-1990s in which Wolverine and other anti-heroes became ubiquitous (he describes this as "Wolverine-mania") and often marketed with gimmick covers. Among later stories, critic Jim Davis considers "Enemy of the State" and "Old Man Logan", both by Millar, to be particularly notable.
=== Plays === Habis, tragédie (1714) Cléarque, tyran d'Héraclée, tragédie (1733 - English translation: Cléarchus, Tyrant of Heraclea, a tragedy) Marsidie reine des Cimbres, tragédie (1735 - English translation: Marsidie, Queen of the Cimbri) Semiramis, tragédie (1737 - English translation: Semiramis, tragedy)
==== Extracellular proteases ==== The green microalgae Chlamydomonas coccoides and Dunaliella sp. and chlorella sphaerkii (a unicellular marine chlorophyte) were found to produce extracellular proteases. The diatom Chaetoceros didymus releases substantial amounts of proteases into the medium, this production is induced by the presence of the lytic bacterium Kordia algicida and is connected to the resistance of this alga against the effects of this bacterium. Some proteases are of functional importance in viral life cycles, thus being attractive targets for drug development.
Sources: en.wikipedia.org
These glands are termed Von Ebner's glands which have also been shown to have another function in the secretion of histatins which offer an early defense (outside of the immune system) against microbes in food, when it makes contact with these glands on the tongue tissue. Sensory information can stimulate the secretion of saliva providing the necessary fluid for the tongue to work with and also to ease swallowing of the food.
Betaine transporter (SLC6A12) InterPro: IPR002983 Creatine transporter (SLC6A8) InterPro: IPR002984 Dopamine neurotransmitter transporter (SLC6A3) InterPro: IPR002436 Inebriated neurotransmitter transporter InterPro: IPR002944 GABA neurotransmitter transporter GAT-1 (SLC6A1) InterPro: IPR002980 GABA neurotransmitter transporter GAT-2 (SLC6A13) InterPro: IPR002981 GABA neurotransmitter transporter GAT-3 (SLC6A11) InterPro: IPR002982 Glycine neurotransmitter transporter, type 1 (SLC6A9) InterPro: IPR003028 Noradrenaline neurotransmitter transporter (SLC6A2) InterPro: IPR002435 Orphan neurotransmitter transporter (SLC6A15) InterPro: IPR002438 Serotonin (5-HT) neurotransmitter transporter, N-terminal (SLC6A4) InterPro: IPR013086 Taurine transporter (SLC6A6) InterPro: IPR002434
In 2005–06, fragrance mix was the third-most-prevalent allergen in USA patch tests (11.5%). 'Fragrance' was voted Allergen of the Year in 2007 by the American Contact Dermatitis Society. An academic study in the United States published in 2016 has shown that "34.7 % of the population reported health problems, such as migraine headaches and respiratory difficulties, when exposed to fragranced products". The composition of fragrances is usually not disclosed in the label of the products, hiding the actual chemicals of the formula, which raises concerns among some consumers. In the United States, this is because the law regulating cosmetics protects trade secrets. In the United States, fragrances are regulated by the Food and Drug Administration if present in cosmetics or drugs, by the Consumer Product Safety Commission if present in consumer products. No pre-market approval is required, except for drugs. Fragrances are also generally regulated by the Toxic Substances Control Act of 1976 that "grandfathered" existing chemicals without further review or testing and put the burden of proof that a new substance is not safe on the EPA. The EPA, however, does not conduct independent safety testing but relies on data provided by the manufacturer. A 2019 study of the top-selling skin moisturizers found 45% of those marketed as "fragrance-free" contained fragrance. Cosmetics are regulated in the United Kingdom and the composition of products must be provided.
=== Product invention === As recently as July 21, 2011, LifeVantage credited McCord as the creator of Protandim on its website. At a 2011 conference for LifeVantage distributors, McCord stated, "I was presented with a list of 41 potential ingredients for a product they wanted to call Protandim, and I went through the list and penciled out, rapidly, about 36 of those ingredients," leaving the 5 ingredients in the current formulation of Protandim. In March 2009, former LifeLine Therapeutics executive, Paul Myhill stated, "We initially decided to hide that fact [that Myhill derived the core composition for Protandim] for marketing purposes and instead rely on the impeccable background of Dr. McCord." In April, 2005, Myhill produced a signed letter from McCord in which McCord stated, "I do not honestly feel that I have made contributions to the intellectual property, up to this point, that would qualify me as an inventor...I must congratulate you and Paul for having framed the concept of Protandim so close to its final embodiment, prior to the beginnings of our association."
=== Target animal safety === In swine, ractopamine is correlated with adverse effects, especially hyperactivity, trembling, and broken limbs, leading to censure by animal rights groups. In a conversation with Boulder Weekly newspaper, Colorado State University Professor of Animal Science Temple Grandin, an expert on animal welfare, described harmful effects of ractopamine on feedlot animals, such as cattle with stiff, sore, and lame limbs, and increased heat stress. In the same column, she also opines that meat from ractopamine-treated animals may be tougher. Ractopamine use is a factor in the incidence of downer pigs, animals that are unable to move or stand.
Sources: en.wikipedia.org
It is a synthetic peptide triagonist that engages GIP, GLP-1, and glucagon receptors. Investigational compounds in this class are studied for metabolic conditions rather than for a single organ system.
No regulatory agency has approved it for any indication. It remains an investigational product studied within controlled clinical trial programs.
A dual agonist engages two receptor targets, typically GIP and GLP-1. A triagonist adds glucagon receptor activity, which is intended to influence energy expenditure alongside appetite and glucose handling.
尚未。它仍处于临床研究阶段，任何监管批准都取决于正在进行的试验结果和提交审评。可公开获取的信息以试验注册和会议摘要为主。